Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Cancer Biomarker Market?

The market size of cancer biomarkers has experienced significant growth in the past few years. Its size is projected to increase from $22.19 billion in 2024 to $25.28 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 13.9%. The historic period’s growth has been influenced by a turn toward personalized medicine, advancements in immunotherapy, changes in regulatory frameworks, a boost in cooperative research efforts, and a focus on non-coding RNAs.

What Growth Rate Is Forecasted for the Cancer Biomarker Market by 2029?

The market size for cancer biomarkers is anticipated to undergo significant expansion in the upcoming years, with an expected valuation of $45.88 billion in 2029 and a compound annual growth rate (CAGR) of 16.1%. The predicted growth in this period can be credited to a transition towards diagnostics that focus on individual patients, the implementation of biomarkers in clinical studies, the development of multiplex biomarker panels, study into non-coding RNAs, and the commercialization of biomarker tests. Notable trends in the forecasted period comprise breakthroughs in the field of genomics, precision medicine strategies, liquid biopsy technologies, advancements in immunotherapy, and the integration of artificial intelligence (AI).

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8492&type=smp

Which Key Companies Are Shaping the Future of the Cancer Biomarker Market?

Major companies operating in the cancer biomarker market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., QIAGEN NV, Illumina Inc., Bio-Rad Laboratories Inc., Abbott Laboratories, bioMérieux SA, Becton Dickinson and Company, Merck & Co. Inc., Bristol-Myers Squibb Company, PerkinElmer Inc., Siemens AG, Exact Sciences Corporation, Novartis AG, Agilent Technologies Inc., Hologic Inc., Myriad Genetics Inc., Foundation Medicine Inc., Guardant Health Inc., Natera Inc., Sysmex Corporation, Biocartis Group NV, NanoString Technologies Inc., Veracyte Inc., Epic Sciences Inc., Cynvenio Biosystems Inc., Genomic Health Inc., Oncocyte Corporation, Exosome Diagnostics Inc., Grail Inc.

Which Factors Are Driving Demand in the Cancer Biomarker Industry?

The cancer biomarker market is expanding due to the escalating rates of cancer occurrences. Defined as the number of new cancer cases of a certain type, occurring in a specified population in a year, the cancer incidence rate is typically expressed as cancers per 100,000 people at risk. Because of the ability of cancer biomarkers to gauge disease risk, differentiate between benign and malignant symptoms, or distinguish one kind of cancer from another, their use is becoming more prevalent. For example, as per the research published by the American Cancer Society in January 2022, it is predicted that there will be 609,360 cancer-related deaths and around 1.9 million new cases of cancer in the U.S in 2022. This amounts to almost 1,670 deaths each day. Consequently, the growth of the cancer biomarker market is predicted to surge in response to the increasing presence of cancer in the future.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=8492&type=smp

How Is the Cancer Biomarker Market Segmented by Several Divisions?

The cancer biomarker market covered in this report is segmented –

1) By Biomarkers Type: Protein Biomarkers, Genetic Biomarkers, Other Cancer Biomarkers

2) By Profiling Technologies: Omics Technologies, Imaging Technologies, Immunoassay, Bioinformatics, Cytogenetics

3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Thyroid Cancer, Kidney Cancer, Other Cancers

4) By Application: Diagnostics, Research And Development, Prognostics, Risk Assessment, Other Applications

Subsegments:

1) By Protein Biomarkers: Tumor-Specific Antigens, Circulating Tumor Protein

2) By Genetic Biomarkers: DNA Mutations, RNA Expression Profiles

3) By Other Cancer Biomarkers: Epigenetic Biomarkers, Metabolomic Biomarkers

What are the Emerging Market Trends Driving the Growth of the Cancer Biomarker Industry?

Prominent businesses in the cancer biomarker industry are concentrating on producing novel solutions like AI-enabled cancer biomarkers, with the aim of improving diagnosis precision and customizing treatment pathways for patients. AI-driven cancer biomarkers are biological markers of cancer that are discerned and examined using artificial intelligence tools. For instance, in September 2023, the American firm Ibex Medical Analytics rolled out Galen Breast HER2, which is an AI-based solution to increase HER2 scoring accuracy and consistency in patients with breast cancer. This pioneering platform assists pathologists by autonomously identifying invasive tumor locations and measuring HER2 expression in congruence with the 2018 ASCO/CAP guidelines. The Galen Breast HER2 solution employs an innovative computational process for analyzing immunohistochemistry (IHC)-dyed slides, giving comprehensive visualizations of staining formations hence enabling pathologists to make knowledgeable treatment choices.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

Which Regions Are Driving Growth in the Cancer Biomarker Market?

North America was the largest region in the cancer biomaker market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer biomarker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8492

This Report Delivers Insight On:

1. How big is the cancer biomarker market, and how is it changing globally?

2. Who are the major companies in the cancer biomarker market, and how are they performing?

3. What are the key opportunities and risks in the cancer biomarker market right now?

4. Which products or customer segments are growing the most in the cancer biomarker market?

5. What factors are helping or slowing down the growth of the cancer biomarker market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model